Stockreport

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals, Inc.  (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com
PDF First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immuno [Read more]